These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19900247)

  • 21. Lessons from abroad.
    Schmidt H; Kreis J
    Hastings Cent Rep; 2009; 39(6):20-2. PubMed ID: 20050367
    [No Abstract]   [Full Text] [Related]  

  • 22. Bridging the gap between methods research and the needs of policy makers: a review of the research priorities of the National Institute for Health and Clinical Excellence.
    Longworth L; Sculpher MJ; Bojke L; Tosh JC
    Int J Technol Assess Health Care; 2011 Apr; 27(2):180-7. PubMed ID: 21447260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Approaches for economic evaluations of health care technologies.
    Tarride JE; Blackhouse G; Bischof M; McCarron EC; Lim M; Ferrusi IL; Xie F; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):307-16. PubMed ID: 19394571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost modeling to justify technology acquisitions.
    Vanden Brink J; Gray S
    Healthc Financ Manage; 1997 Jun; 51(6):72-6. PubMed ID: 10167845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Presentation of economic evaluation results.
    Chaikledkaew U
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S72-80. PubMed ID: 24964702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation in a disconnected healthcare system: problems and suggested solutions from the Australian HTA review.
    Gallego G; Harris A
    Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):615-7. PubMed ID: 21155692
    [No Abstract]   [Full Text] [Related]  

  • 27. [The Danish Health Technology Assessment model. A systematic review of Danish HTAs published by CEMTV from 1998 to 2004].
    Draborg EU
    Ugeskr Laeger; 2006 May; 168(21):2074-8. PubMed ID: 16768927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis.
    Iannazzo S; De Francesco M; Gomez-Ulloa D; Benucci M
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):455-68. PubMed ID: 23977974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health technology assessment.
    Hailey D
    Singapore Med J; 2006 Mar; 47(3):187-92; quiz 193. PubMed ID: 16518551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expanding Health Technology Assessments to Include Effects on the Environment.
    Marsh K; Ganz ML; Hsu J; Strandberg-Larsen M; Gonzalez RP; Lund N
    Value Health; 2016; 19(2):249-54. PubMed ID: 27021760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of perspective in defining economic measures for the evaluation of medical technology.
    Davidoff AJ; Powe NR
    Int J Technol Assess Health Care; 1996; 12(1):9-21. PubMed ID: 8690566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resource allocation and health technology assessment in Australia: views from the local level.
    Gallego G; van Gool K; Kelleher D
    Int J Technol Assess Health Care; 2009 Apr; 25(2):134-40. PubMed ID: 19331706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A regulatory governance perspective on health technology assessment (HTA) in France: the contextual mediation of common functional pressures.
    Barron AJ; Klinger C; Shah SM; Wright JS
    Health Policy; 2015 Feb; 119(2):137-46. PubMed ID: 25458970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Discrete-event simulation models in the economic evaluation of health technologies and health products].
    Rodríguez Barrios JM; Serrano D; Monleón T; Caro J
    Gac Sanit; 2008; 22(2):151-61. PubMed ID: 18420015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality assessment of health economic evaluation.
    Chaikledkaew U; Kittrongsiri K
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S113-8. PubMed ID: 24964708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing the costs of healthcare technologies in clinical trials.
    Johnston K; Buxton MJ; Jones DR; Fitzpatrick R
    Health Technol Assess; 1999; 3(6):1-76. PubMed ID: 10350450
    [No Abstract]   [Full Text] [Related]  

  • 37. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies.
    Drummond M; Manca A; Sculpher M
    Int J Technol Assess Health Care; 2005; 21(2):165-71. PubMed ID: 15921055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Editorial: Pursuing efficiency: a dead end for HTA?
    Jaime Caro J
    Value Health; 2009 Jun; 12 Suppl 2():S49. PubMed ID: 19523185
    [No Abstract]   [Full Text] [Related]  

  • 39. The need for economic evaluation of telemedicine to evolve: the experience in Alberta, Canada.
    Hailey D; Jennett P
    Telemed J E Health; 2004; 10(1):71-6. PubMed ID: 15104918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of health technology assessment reports on decision making in Austria.
    Zechmeister I; Schumacher I
    Int J Technol Assess Health Care; 2012 Jan; 28(1):77-84. PubMed ID: 22233544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.